China indapamide market is estimated to grow at a CAGR of around 4.1% during the forecast period. The market is mainly driven due to growing various heart-related diseases and other diseases in the country. Lack of physical activity, obese population, alcohol consumption, unhealthy diet, and smoking are some major factors leading to the rising number of incidences of these conditions. The rising aging population may further increase the risk of hypertension in China. With the age, arteries get stiffer and thereby blood pressure goes up. Apart from the aging population, the condition has been shown to increase among adults in the country. As per the findings by the researchers at Yale and the Chinese National Center for Cardiovascular Disease published in October 2017, over one-third of adults in China are suffering from high blood pressure. Hypertension raised the risk of severe health problems, such as heart attack and stroke. The use of indapamide supports to reduce the blood pressure and the risk of having other severe condition among patients.

Request a free sample of our report on China Indapamide Market: https://www.omrglobal.com/request-sample/china-indapamide-market

China indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg indapamide. Among these, the market for 1.25 mg indapamide held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

A full report of China Indapamide Market Is available at Global Anti-Acne https://www.omrglobal.com/industry-reports/china-indapamide-market

China Indapamide Market Segmentation

By Product

1.25 MG

2.5 MG

By Application

High Blood Pressure

Heart Failure

Others

Company Profiles

ANI Pharmaceuticals, Inc.

Glenmark Pharmaceuticals Ltd.

Merck KGaA

Sandoz International GmbH

Sanofi S.A.

Shandong Yinfeida Pharmaceutical Co., Ltd.

Supra Chemicals

Suzhou Lixin Pharmaceutical Co., Ltd.

Taj Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/china-indapamide-market

About us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting, and other research-based services.



For More Information, Visit https://www.omrglobal.com/



Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +91 780-304-0404